Details

Autor(en) / Beteiligte

• THIEL, U
• KOSCIELNIAK, E
• FAGIOLI, F
• LUTZ, P
• EHNINGER, G
• SCHNEIDER, P
• SANTUCCI, A
• BADER, P
• GRUHN, B
• FARACI, M
• ANTUNOVIC, P
• STYCZYNSKI, J
• BLAESCHKE, F
• KRÜGER, W. H
• CASTAGNA, L
• ROHRLICH, P
• OUACHEE-CHARDIN, M
• SALMON, A
• PETERS, C
• BREGNI, M
• BURDACH, S
• GRUNEWALD, T. G. P
• BADOGLIO, M
• DIAZ, M. A
• PAILLARD, C
• PRETE, A
• USSOWICZ, M
• LANG, P

Titel

Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment

Ist Teil von

• British journal of cancer, 2013-11, Vol.109 (10), p.2523-2532

Ort / Verlag

Basingstoke: Nature Publishing Group

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• Allogeneic haematopoietic stem cell transplantation (allo-SCT) may provide donor cytotoxic T cell-/NK cell-mediated disease control in patients with rhabdomyosarcoma (RMS). However, little is known about the prevalence of graft-vs-RMS effects and only a few case experiences have been reported. We evaluated allo-SCT outcomes of 30 European Group for Blood and Marrow Transplantation (EBMT)-registered patients with advanced RMS regarding toxicity, progression-free survival (PFS) and overall survival (OS) after allo-SCT. Twenty patients were conditioned with reduced intensity and ten with high-dose chemotherapy. Twenty-three patients were transplanted with HLA-matched and seven with HLA-mismatched grafts. Three patients additionally received donor lymphocyte infusions (DLIs). Median follow-up was 9 months. Three-year OS was 20% (s.e.±8%) with a median survival time of 12 months. Cumulative risk of progression was 67% (s.e.±10%) and 11% (s.e.±6%) for death of complications. Thirteen patients developed acute graft-vs-host disease (GvHD) and five developed chronic GvHD. Eighteen patients died of disease and four of complications. Eight patients survived in complete remission (CR) (median: 44 months). No patients with residual disease before allo-SCT were converted to CR. The use of allo-SCT in patients with advanced RMS is currently experimental. In a subset of patients, it may constitute a valuable approach for consolidating CR, but this needs to be validated in prospective trials.